Pete Gilmore

Peter Gilmore is a Principal in KPMG Strategy with more than 17 years of experience advising senior management teams at leading pharmaceutical, medical device and consumer health companies. Peter supports life sciences clients on both transformation and optimization engagements in Commercial and R&D on issues relating to market access and novel contracting strategies, new product development strategy, launch planning, and commercial model innovation. Peter’s major area of focus is on helping life sciences companies develop strategies for maximizing the value of their portfolios and individual assets in the face of the rapidly evolving and highly uncertain global payer environment.

Peter is a member of KPMG Strategy specializing in R&D portfolio management, product development and commercialization strategies for pharmaceutical companies. Peter has extensive experience with decision analysis, uncertainty and risk analysis, and design and development of complex valuation models that have been adapted for use in the life sciences industry.

Peter’s recent KPMG publications include Ten integrated imperatives for Pharmaceutical Commercial Model Transformation (February 2015); A Bittersweet Pill: While welcoming possibilities for breakthrough innovation Pharma must tackle a resourcing crisis (October 2015) and Specialty Drug Market Access Reality Check: Ten payer pressures to act on now (August 2016).

Peter holds a B.A. in Government from Dartmouth.